Literature DB >> 8500480

Evaluation of two enzyme immunoassays for rapid detection of group B streptococci in pregnant women.

J Wüst1, G Hebisch, K Peters.   

Abstract

The performance of two enzyme immunoassays for rapid detection of group B streptococci (GBS) was evaluated in comparison to culture using cervical swabs from 191 pregnant women. Ten percent of the women harboured GBS. There were two positive results in the Icon assay (Hybritech), both in women with heavy growth in the culture, and four positive results in the Quidel assay (Quidel), two in the women with heavy colonization and one each in women with moderate and light growth of GBS respectively. The sensitivity of both assays was low, being 11% (2/18) for the Icon assay and 24% (4/17) for the Quidel assay. The specificity of both assays was 100%. Both assays could detect > or = 10(6) group B streptococci per swab. A positive result justifies ampicillin prophylaxis due to the high risk for the newborn. A negative result should be confirmed by rapid culture techniques.

Entities:  

Mesh:

Year:  1993        PMID: 8500480     DOI: 10.1007/BF01967589

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  New Granada Medium for detection and identification of group B streptococci.

Authors:  M de la Rosa; M Perez; C Carazo; L Pareja; J I Peis; F Hernandez
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

2.  Rapid detection of group B streptococcal carriage in parturient women using a modified starch serum medium.

Authors:  E E Wang; O Hammerberg; P Lyn; H Q Peng; D Hunter; H Richardson
Journal:  Clin Invest Med       Date:  1988-02       Impact factor: 0.825

3.  Rapid recognition of group-B Streptococci.

Authors:  A K Islam
Journal:  Lancet       Date:  1977-01-29       Impact factor: 79.321

4.  Evaluation of a rapid method for the detection of vaginal group B streptococci in women in labor.

Authors:  E P Reardon; M A Noble; E R Luther; A J Wort; J Bent; M Swift
Journal:  Am J Obstet Gynecol       Date:  1984-03-01       Impact factor: 8.661

5.  Selective intrapartum chemoprophylaxis of neonatal group B streptococcal early-onset disease. I. Epidemiologic rationale.

Authors:  K M Boyer; C A Gadzala; L I Burd; D E Fisher; J B Paton; S P Gotoff
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

6.  A rapid method for detection of group B streptococcal colonization: testing at the bedside.

Authors:  E Wang; H Richardson
Journal:  Obstet Gynecol       Date:  1990-11       Impact factor: 7.661

7.  Prevention of neonatal group B streptococcal sepsis by the use of a rapid screening test and selective intrapartum chemoprophylaxis.

Authors:  W J Morales; D V Lim; A F Walsh
Journal:  Am J Obstet Gynecol       Date:  1986-11       Impact factor: 8.661

8.  Evaluation of a rapid screening test for detecting group B streptococci in pregnant women.

Authors:  P A Granato; M T Petosa
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

9.  Comparison of commercially available group B streptococcal latex agglutination assays.

Authors:  D P Ascher; S Wilson; G W Fischer
Journal:  J Clin Microbiol       Date:  1991-12       Impact factor: 5.948

10.  Ampicillin prevents intrapartum transmission of group B streptococcus.

Authors:  M D Yow; E O Mason; L J Leeds; P K Thompson; D J Clark; S E Gardner
Journal:  JAMA       Date:  1979-03-23       Impact factor: 56.272

View more
  2 in total

1.  Rapid detection of group B streptococcal colonization of the genital tract by a commercial optical immunoassay.

Authors:  K C Carroll; D Ballou; M Varner; H Chun; R Traver; J Salyer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

2.  Significance of Gram's stain in rapid intrapartum screening for maternal carriership of group B streptococcus.

Authors:  A H Adriaanse; H L Muytjens; L A Kollée; J G Nijhuis; J A Hoogkamp-Korstanje
Journal:  Infect Dis Obstet Gynecol       Date:  1995
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.